Skip to main content
The Egyptian Journal of Internal Medicine
Download PDF
  • Original article
  • Open access
  • Published:

Urinary neutrophil gelatinase-associated lipocalin as a marker of kidney injury in Egyptian patients with thalassemia

The Egyptian Journal of Internal Medicine volume 31, pages 343–352 (2019)Cite this article

En

Abstract

Background

Renal disease is a long-term complication that should be recognized in thalassemia, especially with the rise in the average age of this population. Proper assessment of renal function abnormalities in thalassemia can be challenging because of the increased use of iron chelators, which themselves can affect renal function. There is a trend toward earlier detection of glomerular and tubular abnormalities, using early biomarkers of renal dysfunction. However, conflicting data make conclusive correlations difficult to achieve and strong diagnostic statistical parameters for these biomarkers are still lacking. Examples include albumin/creatinine ratio which can predict the initial signs of glomerular impairment, serum cystatin-C, and serum or urinary β-2 microglobulin have received attention as better tools to assess sensitive changes in glomerular filtration rate (GFR) and creatinine clearance in thalassemia as compared with serum creatinine and eGFR. Neutrophil gelatinase-associated lipocalin (NGAL) excretion in urine occurs when there is proximal tubular injury that disrupts NGAL reabsorption or increases NGAL synthesis. Significant correlations between the levels of urinary neutrophil gelatinase-associated lipocalin (uNGAL) and the degree of proteinuria in patients with chronic renal disease from diverse etiologies have been reported.

Aim

The study was to assess the markers of renal injury in β-thalassemia (β-TM) patients and to detect the significance of urinary albumin/creatinine ratio and uNGAL levels, as markers of kidney injury in Egyptian patients with thalassemia.

Materials and methods

This case–control study was conducted on 40 β-TM patients and 45 age-matched and gender-matched healthy controls, 27 women and 13 men, with a mean age of 29±9 years and for controls 28±5 years.

The majority of enrolled patients (22) were thalassemia intermediate. One-third of the patients were receiving iron chelation therapy, 78.6% on deferasirox, and 21.4% on deferiprone. All patients were subjected to through history taking, physical examination, and routine laboratory investigation. Tests were done for the diagnosis of thalassemia and to identify the type of thalassemia. Type and dose of Iron chelation therapy was recorded treatment: type and dose of chelation. Measurement of uNGAL and calculation of uNGAL/creatinine ratio were done. eGFR was calculated according to the original modification of diet in renal disease equation eGFR (ml/min/1.73 m2). Chronic kidney disease was defined and graded according to KDIGO 2012.

Results

The results show that there is a statistically significant difference between cases and controls regarding uNGAL level as median was 498.0 ng/ml for cases compared with controls 423.3 ng/ml with a P value of 0.034. There is a statistically significant difference between cases and controls regarding uNGAL/creatinine ratio as the median was 481.75 ng/mg for cases compared with 333.79 with a P value of 0.003. There is no significant correlation between uNGAL (ng/ml) and dose of iron chelator, duration of iron chelator, eGFR, hemoglobin (Hg) level, serum ferritin, and albumin/creatinine ratio. There is no significant correlation between uNGAL/creatinine ratio (ng/mg) and eGFR, Hg level, serum ferritin, and albumin/creatinine ratio. eGFR was significantly higher (hyperfiltration) in cases compared with controls, with a median of 169.8 ml/min/1.73 m3 compared with 119.6 ml/min/1.73 m3, with a P value of less than 0.001. There was a statistically significant difference between cases and controls regarding albumin/creatinine ratio (µg/mg creatinine) as the median was 29.4 µg/mg creatinine for cases compared with controls 10.0 µg/mg creatinine with a P value of less than 0.001.

Conclusion

This study showed that assessment of albumin/creatinine ratio, uNGAL, and uNGAL/creatinine ratio, can be regarded as potential early biomarkers of renal dysfunction in β-TM patients.

References

  1. Diwani M. Erythroblastic anaemia with bone changes in Egyptian children: Possible Cooley’s Type. Arch Dis Child 1944; 19: 163–168.

    Article  CAS  Google Scholar 

  2. Taher AT, Weatherall DJ, Cappellini MD. Thalassaemia. Lancet 2017; 391: 155–167.

    Article  Google Scholar 

  3. Haines D, Martin M, Carson S et al. Pain in thalassaemia: the effects of age on pain frequency and severity. Br J Haematol 2013; 160: 680.

    Article  Google Scholar 

  4. Cappellini MD, Cohen A, Porter J et al. Guidelines for the management of transfusion dependent thalassaemia (TDT). Nicosia (CY): Thalassaemia International Federation; 2014.

    Google Scholar 

  5. Ponticelli C, Musallam KM, Cianciulli P et al. Renal complications in transfusion-dependent beta thalassaemia. Blood Rev 2010; 24: 239–244.

    Article  Google Scholar 

  6. Cappellini MD, Quebe-Fehling E, Pallaud C et al. Exploring the clinical utility of renal safety biomarkers during iron chelation therapy in patients with β-thalassemia and other anemias. Blood 2017; 130: 4762.

    Google Scholar 

  7. Hellmann F, Verdi M, Schlemper BR Jr et al. 50th anniversary of the Declaration of Helsinki: the double standard was introduced. Arch Med Res 2014; 45:600–601.

    Article  Google Scholar 

  8. Al-Khabori M, Bhandari S, Al-Rasadi K et al. Correlation of iron overload and glomerular filtration rate estimated by cystatin C in patients with beta-thalassemia major. Hemoglobin 2014; 38: 365–368.

    Article  CAS  Google Scholar 

  9. Bhandari S, Galanello R. Renal aspects of thalassaemia a changing paradigm. Eur J Haematol 2012; 89: 187–197.

    Article  CAS  Google Scholar 

  10. Mallat NS, Mallat SG, Musallam KM et al. Potential mechanisms for renal damage in beta-thalassemia. J Nephrol 2013; 26: 821–828.

    Article  Google Scholar 

  11. Sleiman J, Tarhini A, Taher AT. Renal complications in thalassemia. Thalassemia Rep 2018; 8: 7481.

    Google Scholar 

  12. Paragas N, Qiu A, Hollmen M, Nickolas T, Devarajan P, Barasch J. NGAL-siderocalin in kidney disease. Biochim Biophys Acta 2012; 1823: 1451–1458.

    Article  CAS  Google Scholar 

  13. Quinn CT, Johnson VL, Kim HY et al. Thalassemia Clinical Research Network: renal dysfunction in patients with thalassaemia. Br J Haematol 2011; 153: 111–117.

    Article  CAS  Google Scholar 

  14. Annayev A, Karakas Z, Karaman S et al. Glomerular and tubular functions in children and adults with transfusion dependent thalassemia. Turk J Haematol 2017; 35: 66–70.

    Article  Google Scholar 

  15. Behairy OG, Abd Almonaem ER, Abed NT et al. Role of serum cystatin-C and beta-2 microglobulin as early markers of renal dysfunction in children with beta thalassemia major. Int J Nephrol Renovasc Dis 2017; 10:261–268.

    Article  CAS  Google Scholar 

  16. Ziyadeh FN, Musallam KM, Mallat NS et al. Glomerular hyperfiltration and proteinuria in transfusion-independent patients with beta-thalassemia intermedia. Nephron Clin Pract 2012; 121: c136–c143.

    CAS  PubMed  Google Scholar 

  17. Fibach E, Rachmilewitz E. The role of oxidative stress in hemolytic anemia. Curr Mol Med 2008; 8: 609619.

    Article  Google Scholar 

  18. Palatini P. Glomerular hyperfiltration: a marker of early renal damage in pre-diabetes and pre-hypertension. Nephrol Dial Transplant 2012; 27: 1708–1714.

    Article  Google Scholar 

  19. Smolkin V, Halevy R, Levin C et al. Renal function in children with beta-thalassemia major and thalassemia intermedia. Pediatr Nephrol 2008; 23: 1847–1851.

    Article  Google Scholar 

  20. Musallam KM, Taher TA. Mechanisms of renal disease in β-thalassemia. J Am Soc Nephrol 2012; 23: 1299–1302.

    Article  CAS  Google Scholar 

  21. Tanous O, Azulay Y, Dujovny T et al. Renal function in transfusion-dependent β-thalassemia patients: a decade of follow-up and comparison between chelation regimes. Blood 2017; 130: 949.

    Google Scholar 

  22. King SM, Donangelo CM, Knutson MD et al. Daily supplementation with iron increases lipid peroxidation in young women with low iron stores. Exp Biol Med (Maywood) 2008; 233: 701–707.

    Article  CAS  Google Scholar 

  23. Bastani MN, Bokharaei-Salim F, Keyvani H et al. Prevalence of occult hepatitis C virus infection in Iranian patients with beta thalassemia major. Arch Virol 2016; 161: 1899–1906.

    Article  CAS  Google Scholar 

  24. Chandra J, Chaudhary H, Pemde H et al. Safety and efficacy of deferasirox in multitransfused Indian children with thalassemia major. Ann Trop Paediatr 2011; 31: 47–51.

    Article  CAS  Google Scholar 

  25. Rheault MN, Bechtel H, Neglia JP, Kashtan CE. Reversible Fanconi syndrome in a pediatric patient on deferasirox. Pediatr Blood Cancer 2011; 56: 674–676.

    Article  Google Scholar 

  26. Agarwal R, Leehey DJ, Olsen SM, Dahl NV. Proteinuria induced by parenteral iron in chronic kidney disease a comparative randomized controlled trial. Clin J Am Soc Nephrol 2011; 6: 114–121.

    Article  CAS  Google Scholar 

  27. Sleiman J, Tarhini A, Bou-Fakhredin R et al. Non-transfusion dependent thalassemia: an update on complications and management. Int J Mol Sci 2018; 19: 182.

    Article  Google Scholar 

  28. Deveci B, Kurtoglu A, Kurtoglu E et al. Documentation of renal glomerular and tubular impairment and glomerular hyperfiltration in multitransfused patients with beta thalassemia. Ann Hematol 2016; 95: 375–381.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Cairo University, Cairo, Egypt

    Ibrahim Z. Fouad, Maggie S. ElNahid MD & Maha F. Youssef

  2. Department of Clinical and Chemical Pathology, Helwan University, Helwan, Egypt

    Yasmine M. Amroussy

Authors
  1. Ibrahim Z. Fouad
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maggie S. ElNahid MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maha F. Youssef
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yasmine M. Amroussy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maggie S. ElNahid MD.

Additional information

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fouad, I.Z., ElNahid, M.S., Youssef, M.F. et al. Urinary neutrophil gelatinase-associated lipocalin as a marker of kidney injury in Egyptian patients with thalassemia. Egypt J Intern Med 31, 343–352 (2019). https://doi.org/10.4103/ejim.ejim_114_18

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.4103/ejim.ejim_114_18

Keywords